22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
California law has specific requirements regarding the payment of final wages to terminated employee...
Read More >
In December 2020, the United States Department of Transportation (DOT) amended the small business si...
Read More >
The U.S. Federal Trade Commission (FTC) and U.S. Department of Justice Antitrust Division (“DOJ” a...
Read More >
In a petition for a writ of mandamus filed on April 29, 2019 with the U.S. Court of Appeals for the ...
Read More >
The Delaware Court of Chancery (the Court) in In re Homefed Corporation Stockholder Litigation chron...
Read More >
The following are some immigration enforcement and compliance trends we are watching closely heading...
Read More >